A Novel 1,3-Beta- d -Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Ibrexafungerp (IBX) (formerly SCY-078) is a novel glucan synthase inhibitor whose oral availability is being evaluated for efficacy against vulvovaginal candidiasis (VVC). Bioavailability and in vitro activity are important efficacy indicators, but accepted susceptibility methods do not always accurately predict activity in an acidic environment, such as the vagina.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurrent vulvovaginal candidiasis
Sobel, J. D. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.06.067 · Cited by 502 · cited 1×
“VVC affects approximately 70% to 75% of women at least once in their lifetime (3), and RVVC, defined as 3 or more episodes of symptomatic acute Candida vaginitis in a 12-month period, is estimated to occur in 6% to 9% of women during their reproductive years (10).”
BackgroundThe Trailing End Point Phenotype in Antifungal Susceptibility Testing Is pH Dependent
Marr, K. A., Rustad, T. R., Rex, J. H., & White, T. C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.6.1383 · Cited by 145 · cited 1×
“shown that an acidic pH tends to result in higher MICs of FLU for some Candida species (7), which in turn may indicate true FLU resistance.”
BackgroundSCY-078 is fungicidal against Candida species in time-kill studies
Scorneaux, B., Angulo, D., Borroto-Esoda, K., Ghannoum, M., Peel, M., & Wring, S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01961-16 · Cited by 88
Self-citationGhannoum, M., Long, L., Larkin, E. L., Isham, N., Sherif, R., Borroto-Esoda, K., Barat, S., & Angulo, D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00244-18 · Cited by 80 · cited 1×
“IBX has also shown broad-spectrum activity against Aspergillus strains (9), and while these in vitro tests would predict therapeutic success in cases such as invasive candidiasis or aspergillosis, the effect of an acidic environment on the activity of IBX is not known.”
BackgroundSelf-citationWiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Pizzini, J., Catano, G., & Patterson, T. F. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx422 · Cited by 43
Cited by
The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species
Garcia-Rubio, R., de Oliveira, H. C., Rivera, J., & Trevijano-Contador, N. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02993 · Cited by 917
“In addition, there is a novel drug called ibrexafungerp (SCY-078) that is a glucan synthase inhibitor belonging to the triterpenoid antifungal class and shows a broad in vitro and in vivo activity against a broad spectrum ofCandida (Larkin et al., 2019).”
BackgroundThe Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“In another study, ibrexafungerp accumulation was shown in vaginal tissue and fluid with a tissue concentration of twofold to fivefold higher than plasma concentrations and supporting the recent approval for the treatment of Candida vaginitis using a single-day 600-mg treatment (300 mg twice-daily dosage) [118].”
ResultIbrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129
Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods
Satora, M., Grunwald, A., Zaremba, B., Frankowska, K., Żak, K., Tarkowski, R., & Kułak, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165376 · Cited by 84
“Recently, two new drugs characterized by higher efficacy in the treatment of VVC and less potential to cause side effects have appeared— oteseconazole and ibrexafungerp [13,14].”
BackgroundSchwebke, J. R., Sobel, R., Gersten, J. K., Sussman, S. A., Lederman, S. N., Jacobs, M. A., Chappell, B. T., Weinstein, D. L., Moffett, A. H., Azie, N. E., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab750 · Cited by 82
Self-citationNunnally, N. S., Etienne, K. A., Angulo, D., Lockhart, S. R., & Berkow, E. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01692-19 · Cited by 66
Self-citationGamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.642358 · Cited by 58
“demonstrated the efficacy of ibrexafungerp in lower pH environments by evaluating the activity of the drug against Candida species isolated from patients with vulvovaginitis (Larkin et al., 2019).”
BackgroundInfluentialSelf-citationOral Ibrexafungerp: An Investigational Agent for the Treatment of Vulvovaginal Candidiasis
Azie, N., Angulo, D., Dehn, B., & Sobel, J. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791820 · Cited by 46
Self-citationPharmacokinetics and Pharmacodynamics of Ibrexafungerp
McCarthy, M. W. (2022) · Drugs in R&D · doi:10.1007/s40268-021-00376-x · Cited by 28
New Antifungals for Vulvovaginal Candidiasis: What Is Their Role?
Sobel, J. D. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad002 · Cited by 23
Metadata
- Authors
- Larkin, E. L., Long, L., Isham, N., Borroto-Esoda, K., Barat, S., Angulo, D., Wring, S., & Ghannoum, M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2019-05
- Volume
- 63
- Issue
- 5
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2921444777
- Cited by
- 52
- References
- 5
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.